Src inhibitor dasatinib sensitized gastric cancer cells to cisplatin

[1]  Yida Lu,et al.  High ATF4 Expression Is Associated With Poor Prognosis, Amino Acid Metabolism, and Autophagy in Gastric Cancer , 2021, Frontiers in Oncology.

[2]  Ji‐Hyun Lee,et al.  Phase II Study of 5-Fluorouracil, Oxaliplatin plus Dasatinib (FOLFOX-D) in First-Line Metastatic Pancreatic Adenocarcinoma. , 2021, The oncologist.

[3]  S. Krähenbühl,et al.  Imatinib and Dasatinib Provoke Mitochondrial Dysfunction Leading to Oxidative Stress in C2C12 Myotubes and Human RD Cells , 2020, Frontiers in Pharmacology.

[4]  Han C. Dan,et al.  Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway , 2019, BMC Cancer.

[5]  Xin Zhang,et al.  ROS Reduction Does Not Decrease the Anticancer Efficacy of X-Ray in Two Breast Cancer Cell Lines , 2019, Oxidative medicine and cellular longevity.

[6]  J. Finlay,et al.  Targeting Upstream Kinases of STAT3 in Human Medulloblastoma cells. , 2019, Current cancer drug targets.

[7]  R. Ferraro,et al.  Calcium-Dependent Src Phosphorylation and Reactive Oxygen Species Generation Are Implicated in the Activation of Human Platelet Induced by Thromboxane A2 Analogs , 2018, Front. Pharmacol..

[8]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[9]  Dafydd G. Thomas,et al.  Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib , 2018, JAMA oncology.

[10]  A. Giordano,et al.  Effects of antioxidants on apoptosis induced by dasatinib and nilotinib in K562 cells , 2018, Journal of cellular biochemistry.

[11]  Takako Kawakita,et al.  Growth inhibitory effect of the Src inhibitor dasatinib in combination with anticancer agents on uterine cervical adenocarcinoma cells , 2017, Experimental and therapeutic medicine.

[12]  S. Ng,et al.  Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. , 2017, Gastroenterology.

[13]  M. Ychou,et al.  Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer , 2017, Clinical Cancer Research.

[14]  Elie Maza,et al.  In Papyro Comparison of TMM (edgeR), RLE (DESeq2), and MRN Normalization Methods for a Simple Two-Conditions-Without-Replicates RNA-Seq Experimental Design , 2016, Front. Genet..

[15]  M. Humbert,et al.  Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. , 2016, The Journal of clinical investigation.

[16]  D. Majhen,et al.  Integrin αvβ3 expression in tongue squamous carcinoma cells Cal27 confers anticancer drug resistance through loss of pSrc(Y418). , 2016, Biochimica et biophysica acta.

[17]  L. Marín-Gómez,et al.  Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src , 2016, Oncotarget.

[18]  Q. Zhan,et al.  Dasatinib enhances cisplatin sensitivity in human esophageal squamous cell carcinoma (ESCC) cells via suppression of PI3K/AKT and Stat3 pathways. , 2015, Archives of biochemistry and biophysics.

[19]  S. McCall,et al.  Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer , 2014, Investigational New Drugs.

[20]  J. Boerner,et al.  Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells. , 2013, The Journal of surgical research.

[21]  J. Wright,et al.  Phase II study of dasatinib (BMS-354825) in patients with metastatic adenocarcinoma of the pancreas. , 2013, The oncologist.

[22]  Yingyan Yu,et al.  Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells , 2013, Cancer Chemotherapy and Pharmacology.

[23]  A. Berchuck,et al.  A Phase I Trial of Dasatinib, an Src-Family Kinase Inhibitor, in Combination with Paclitaxel and Carboplatin in Patients with Advanced or Recurrent Ovarian Cancer , 2012, Clinical Cancer Research.

[24]  Qiaojun He,et al.  Oxidative stress is involved in Dasatinib-induced apoptosis in rat primary hepatocytes. , 2012, Toxicology and applied pharmacology.

[25]  N. Ibrahim,et al.  Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study , 2011, Clinical Cancer Research.

[26]  Mario Campone,et al.  A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor–Positive Breast Cancer , 2011, Clinical Cancer Research.

[27]  V. Papadimitrakopoulou,et al.  Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma , 2011, Cancer.

[28]  A. Berchuck,et al.  Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells. , 2011, Gynecologic oncology.

[29]  M. Cameron,et al.  Metabolism considerations for kinase inhibitors in cancer treatment , 2010, Expert opinion on drug metabolism & toxicology.

[30]  K. B. Garbutcheon-Singh,et al.  Advances in platinum chemotherapeutics. , 2010, Chemistry.

[31]  G. Sonpavde,et al.  Dasatinib Is Preclinically Active against Src-Overexpressing Human Transitional Cell Carcinoma of the Urothelium with Activated Src Signaling , 2010, Molecular Cancer Therapeutics.

[32]  Shi-Yong Sun.  N-acetylcysteine, reactive oxygen species and beyond , 2010, Cancer biology & therapy.

[33]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[34]  Hua Yu,et al.  Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma , 2009, Melanoma research.

[35]  L. Ellis,et al.  Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. , 2009, Cancer research.

[36]  Ignacio Wistuba,et al.  Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion , 2007, Molecular Cancer Therapeutics.

[37]  A. Reeve,et al.  Destabilized adhesion in the gastric proliferative zone and c-Src kinase activation mark the development of early diffuse gastric cancer. , 2007, Cancer research.

[38]  M. Baccarani,et al.  Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. , 2007, Blood.

[39]  M. J. Hannon.  Metal-based anticancer drugs: From a past anchored in platinum chemistry to a post-genomic future of diverse chemistry and biology , 2007 .

[40]  Moshe Talpaz,et al.  Dasatinib (BMS-354825) Tyrosine Kinase Inhibitor Suppresses Invasion and Induces Cell Cycle Arrest and Apoptosis of Head and Neck Squamous Cell Carcinoma and Non–Small Cell Lung Cancer Cells , 2005, Clinical Cancer Research.

[41]  J. Parsons,et al.  Src family kinases, key regulators of signal transduction , 2004, Oncogene.

[42]  S. Parsons,et al.  c-Src and cooperating partners in human cancer. , 2004, Cancer cell.

[43]  Ping Chen,et al.  Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.

[44]  H. Espejo,et al.  [Gastric cancer]. , 1996, Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru.

[45]  R. Grimble.  Nutritional antioxidants and the modulation of inflammation: theory and practice. , 1994, New horizons.